<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT911-5021</title>
	</head>
	<body>
		<main>
			<p>910416 FT  16 APR 91 / International Company News: Upjohn advances to Dollars 133m after 11% sales gain UPJOHN, the US pharmaceuticals and health care services company, yesterday recorded a 15 per cent improvement in first-quarter earnings from continuing operations on an 11 per cent gain in sales. The company, which makes the Rogaine treatment for baldness and the Xanax anti-anxiety drug, had net income of Dollars 133.3m on sales of Dollars 799.4m in the first quarter ended March 31, against net earnings of Dollars 114.3m on sales of Dollars 723.4m a year earlier. Operating income rose 3 per cent in the latest quarter to Dollars 180m. Upjohn spent Dollars 115.3m, or 14 per cent of sales, on research and development in the first three months of 1991. Sales of health care products rose 10 per cent, led by Ansaid, a non-steroidal anti-inflammatory agent, and Rogaine. American Cyanamid, whose operations include drugs, medical products, chemicals and agricultural products, lifted first-quarter net earnings from Dollars 90.9m, or 95 cents a share, to Dollars 104.8m, or Dollars 1.12, on sales up to Dollars 1.31bn from Dollars 1.15bn.</p>
		</main>
</body></html>
            